Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527832) titled 'An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan' on April 7.

Study Type: Observational

Primary Sponsor: Pfizer

Condition: Colorectal Cancer

Intervention: Drug: Bevacizumab-Pfizer Biosimilar

Recruitment Status: Not recruiting

Date of First Enrollment: May 1, 2026

Target Sample Size: 1000

To know more, visit https://clinicaltrials.gov/study/NCT07527832

Published by HT Digital Content Services with permission from Health Daily Digest....